Dr Lal Pathlabs Ltd Share Price
As on 18 November 2025 at 23:49 IST
Dr Lal PathLabs Q1 FY26 Results:
Net profit for the period increased 24.5% to ₹132 crores in Q1 FY26, from ₹106 crores in Q1 FY25. Total income for the quarter increased 12% year-on-year to ₹698 crores from ₹622.5 crores.
About Dr Lal Pathlabs Ltd
Dr Lal PathLabs Ltd is India's leading diagnostic and related healthcare testing provider. It operates in the healthcare sector. Dr Lal PathLabs has been in business since 1949. This long history of many decades underscores the company’s experience and reliability. The headquarters of Dr. Lal PathLabs is located in New Delhi, India, serving as the central hub for its extensive network of laboratories and collection centers. Dr Lal PathLabs offers a wide array of diagnostic products and services. These include blood tests, urine tests, and tests on other human body viscera. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
1.62%
Over 6 Months
13.02%
Over 1 Year
6.42%
Over 3 Years
31.25%
Dr Lal Pathlabs Ltd Summary
Close ₹3,158.30
Open ₹3,154.50
High ₹3,164.40
Low ₹3,129.50
Volume 67,138
Net Turnover (in Cr) ₹21.12
52Wk High ₹3,540
52Wk Low ₹2,293.55
52Wk High / Low
2,293.55
3,540
Dr Lal Pathlabs Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹26,458.82
EPS (TTM) 63.12
Book Value (BV) 279.43
Div. Yield 0.76 %
P/E (TTM) 50.03
Price/Book Value 11.30
Delivery % 67.21 %
Face Value 10
Key Ratios
PE Ratio 41.66
PB Ratio 9.71
EV to Sales 8.50
PEG Ratio 1.43
ROA 21.76
ROE 24.65
Debt-Equity 0.05
Net Profit Margin 21.15
Operating Profit Margin 33.04
Dr Lal Pathlabs Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,554.82 | 2,295.81 | 2,058.60 | 2,139.95 | 1,632.60 |
| Total Expenses | 1,930.03 | 1,790.36 | 1,714.77 | 1,664.97 | 1,238.19 |
| Profit Before Tax | 624.80 | 505.45 | 343.83 | 474.98 | 394.41 |
| Profit After Tax | 492.25 | 362.29 | 241.08 | 350.29 | 296.48 |
| Operating Profit After Depreciation | 647.10 | 534.81 | 381.36 | 505.16 | 410.41 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,134.99 | 1,195.52 | 1,307.03 | 1,375.83 | 450.74 |
| Total Non Current Assets | 1,353.28 | 1,329.27 | 1,412.48 | 1,478.07 | 516.16 |
| Total Current Assets | 1,363.51 | 1,126.70 | 973.09 | 875.15 | 1,145.17 |
| Total Assets | 2,716.79 | 2,455.96 | 2,385.56 | 2,353.22 | 1,661.33 |
| Total Shareholder's Fund | 2,172.72 | 1,849.28 | 1,666.30 | 1,508.08 | 1,245.06 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 568.89 | 535.33 | 456.03 | 446.69 | 398.15 |
| Net Cash Used In Investing Activities | -303.16 | -24.27 | -287.31 | -449.25 | -212.02 |
| Net Cash Used In Financing Activities | -334.03 | -413.86 | -283.18 | 136.45 | -138.56 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,463.14 | 2,026.86 | 1,815.63 | 1,925.72 | 1,541.82 |
| Total Expenses | 1,841.86 | 1,510.89 | 1,424.80 | 1,466.33 | 1,167.78 |
| Profit Before Tax | 621.28 | 515.97 | 390.83 | 459.39 | 374.04 |
| Profit After Tax | 497.26 | 384.37 | 292.36 | 344.05 | 280.11 |
| Operating Profit After Depreciation | 642.78 | 542.81 | 425.21 | 487.92 | 388.87 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,017.83 | 310.67 | 363.45 | 370.13 | 303.55 |
| Total Non Current Assets | 1,343.67 | 1,494.89 | 1,510 | 1,517.53 | 483.78 |
| Total Current Assets | 1,277.28 | 920.55 | 810.17 | 696.39 | 1,089.30 |
| Total Assets | 2,620.95 | 2,415.44 | 2,320.17 | 2,213.92 | 1,573.08 |
| Total Shareholder's Fund | 2,134.23 | 1,899.66 | 1,689.86 | 1,476.47 | 1,217.09 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 540 | 477.60 | 427.53 | 423.81 | 373.36 |
| Net Cash Used In Investing Activities | -293 | 31.91 | -288.47 | -448.50 | -195.19 |
| Net Cash Used In Financing Activities | -324.75 | -404 | -270.05 | 142.04 | -135.74 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 730.60 | 669.80 | 602.60 | 596.70 | 660.20 |
| Total Expenses | 506.50 | 477.50 | 433.60 | 442.70 | 457.70 |
| Profit Before Tax | 203.60 | 181.10 | 153.40 | 138.30 | 183.10 |
| Profit After Tax | 152.20 | 134 | 155.50 | 98.10 | 130.80 |
| Operating Profit after Depreciation | 248.90 | 220.40 | 194.80 | 179.10 | 224.40 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 699.60 | 640.70 | 577.20 | 569.20 | 630.90 |
| Total Expenses | 484.50 | 457.30 | 418.10 | 418.20 | 436.90 |
| Profit Before Tax | 194.80 | 172.40 | 144.90 | 143.60 | 179 |
| Profit After Tax | 145.70 | 129.30 | 148.40 | 105.40 | 128.80 |
| Operating Profit after Depreciation | 237.90 | 209.70 | 184.30 | 182.30 | 218.20 |
Dr Lal Pathlabs Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 3,137.07
S2 3,115.83
S3 3,102.17
Pivot 3,150.73
R1 3,171.97
R2 3,185.63
R3 3,206.87
Moving Average
20 SMA 3,118.22
50 SMA 3,180.80
100 SMA 3,132.47
200 SMA 2,919.25
Dr Lal Pathlabs Ltd Corporate Actions
Dr Lal Pathlabs Ltd
₹7.0/Share
Announcement Date 07 Nov 2025
Record Date 07 Nov 2025
Div Yield 70%
Dr Lal Pathlabs Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Max Healthcare Institute Ltd | ₹1,121.90 | ₹1,09,099.45 |
| Apollo Hospitals Enterprise Ltd | ₹7,488.40 | ₹1,07,671.70 |
| Fortis Healthcare Ltd | ₹944.15 | ₹71,279.37 |
| Narayana Hrudayalaya Ltd | ₹2,027.90 | ₹41,442.33 |
| Aster DM Healthcare Ltd | ₹678.35 | ₹35,146.74 |
Dr Lal Pathlabs Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Nippon India Pharma Fund | 2.29% |
| UTI-Flexi Cap Fund | 1.46% |
| Sundaram Mid Cap Fund | 1.23% |
| Aditya Birla SL Flexi Cap Fund | 1.06% |
| PGIM India Midcap Fund | 1.05% |
Dr Lal Pathlabs Ltd News
Dr Lal Pathlabs approves bonus issue of 1:1
At meeting held on 31 October 2025
31 Oct 2025, 05:03 pm
Board of Dr. Lal PathLabs recommends interim dividend
Of Rs 7 per share
31 Oct 2025, 04:02 pm
Dr Lal Pathlabs gains as board to mull bonus issue plan on 31st Oct'25
Dr Lal PathLabs added 2.58% to Rs 3,123.20 after the company's board is scheduled to meet on 31 October 2025 to consider a bonus share issue.
27 Oct 2025, 10:44 am
Dr. Lal PathLabs to hold board meeting
On 31 October 2025
25 Oct 2025, 11:22 am
Dr Lal Pathlabs approves proposal for acquisition of immovable property
At board meeting held on 23 September 2025
24 Sep 2025, 01:42 pm
Dr Lal Pathlabs Ltd Stock Analysis
- Annual revenue for Dr Lal Pathlabs Ltd increased by 21.52% to ₹2,463.14 crore in FY 2025 from ₹2,026.86 crore in FY 2024.
- Annual Net Profit for Dr Lal Pathlabs Ltd increased by 29.37% to ₹497.26 crore in FY 2025 from ₹384.37 crore in FY 2024.
- Promoter Shareholding in Dr Lal Pathlabs Ltd decreased by 1.07% in the most recent quarter, from 53.79% in June 2025 to 53.22% in September 2025.
- Dr Lal Pathlabs Ltd delivered a 1-year return of 6.42% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Dr Lal Pathlabs Ltd share price moved down by 0.78% from its previous close of INR ₹3,158.30. The latest Dr Lal Pathlabs Ltd share price is INR ₹3,133.70.
- Dr Lal Pathlabs Ltd share price today has been at a low of 3,130 and a high of 3,168. Over the past 52 weeks, the Dr Lal Pathlabs Ltd share price has seen a low of 2,293.55 and a high of 3,540.
About Dr Lal Pathlabs Ltd
Dr Lal PathLabs Ltd is India's leading diagnostic and related healthcare testing provider. The company offers comprehensive diagnostic services, which include routine blood tests. It also provides specialized tests for viral and bacterial infections. These services are crucial for the early detection and management of various health conditions. This makes Dr. Lal PathLabs a vital player in the healthcare sector.
Operating within the healthcare sector, Dr. Lal PathLabs specializes in diagnostics and pathology. The company has been in business since 1949. This long history of many decades underscores the company’s experience and reliability. The headquarters of Dr. Lal PathLabs is located in New Delhi, India. It is the central hub for the company's extensive network of laboratories and collection centers.
The company was founded by the late Dr. S. K. Lal, who laid the foundation for what has become one of India’s most trusted diagnostic service providers. The company's promoters include Arvind Lal with a 30.81% stake. A team of professional managerial promoters manages the operations of the company-
While Dr. Lal PathLabs is a significant player in the Indian diagnostics market, it is not currently the largest in terms of market share. Additionally, it does not hold the top position in market capitalization. However, it is recognized for its extensive network and high-quality services.
The registered office of Dr Lal PathLabs Ltd is in Rohini, New Delhi, and the registrar's office is in C-1 Block LS, New Delhi. Dr. Lal PathLabs Ltd is a well-established and trusted name in the Indian healthcare sector. It is known for its comprehensive diagnostic services and commitment to quality and innovation.
The importance of Dr Lal PathLabs extends beyond just providing diagnostic services. The company has been a pioneer in the Indian diagnostics industry since its inception in 1949. With over seven decades of experience, Dr Lal PathLabs has built a reputation for reliability and quality. This long-standing presence in the market has allowed the company to develop a deep understanding of the population's healthcare needs. As a result, it can offer relevant and high-quality services.
Headquartered in New Delhi, Dr Lal PathLabs operates an extensive network of laboratories and collection centers across India. This widespread presence ensures that people from various regions have access to essential diagnostic services. The company’s network includes over 200 clinical laboratories, over 2,500 patient service centers, and around 6,500 pick-up points. This extensive reach makes it easier for patients to get their tests done conveniently without traveling long distances.
The company was founded by the late Dr. S. K. Lal, a visionary who recognized the need for reliable diagnostic services in India. Today, Dr Lal PathLabs is promoted by Dr. Arvind Lal, who continues to uphold the legacy of quality and innovation established by his father. Under his leadership, the company has embraced modern technologies and practices. This commitment ensures that it remains at the forefront of the diagnostics industry.
The company’s commitment to quality is evident in its accreditation and certifications. Dr. Lal PathLabs is accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). Additionally, it holds accreditation from the College of American Pathologists (CAP). These accreditations are a testament to the company’s adherence to international standards of quality and reliability. Patients can trust that the test results from Dr Lal PathLabs are accurate and dependable.
While Dr Lal PathLabs is a significant player in the Indian diagnostics market, it is not currently the largest in terms of market share or market capitalization. However, it is recognized for its extensive network and high-quality services. The company’s focus on quality and customer satisfaction has helped it build a loyal customer base.
Promoter shareholding is an essential aspect of Dr Lal PathLabs’ corporate structure. The promoters hold a significant stake in the company, ensuring strong governance and strategic direction. This promoter involvement is crucial for maintaining the company’s vision and values. These values are centered around quality, innovation, and customer satisfaction.
The company also maintains a robust management team and a clear governance framework to ensure transparency and accountability. This solid corporate governance structure helps maintain stakeholders' trust, including patients, investors, and employees.
Operating within the healthcare sector, Dr. Lal PathLabs specializes in diagnostics and pathology. The company has been in business since 1949. This long history of many decades underscores the company’s experience and reliability. The headquarters of Dr. Lal PathLabs is located in New Delhi, India. It is the central hub for the company's extensive network of laboratories and collection centers.
The company was founded by the late Dr. S. K. Lal, who laid the foundation for what has become one of India’s most trusted diagnostic service providers. The company's promoters include Arvind Lal with a 30.81% stake. A team of professional managerial promoters manages the operations of the company-
- Arvind Lal
- Om Prakash Manchanda
- Vandana Lal
- Rahul Sharma
- Archana Lal Erdmann
While Dr. Lal PathLabs is a significant player in the Indian diagnostics market, it is not currently the largest in terms of market share. Additionally, it does not hold the top position in market capitalization. However, it is recognized for its extensive network and high-quality services.
The registered office of Dr Lal PathLabs Ltd is in Rohini, New Delhi, and the registrar's office is in C-1 Block LS, New Delhi. Dr. Lal PathLabs Ltd is a well-established and trusted name in the Indian healthcare sector. It is known for its comprehensive diagnostic services and commitment to quality and innovation.
Importance of the Dr Lal PathLabs Limited
Dr Lal PathLabs Ltd plays a crucial role in the healthcare sector, particularly in diagnostics and pathology. The company provides a wide range of essential diagnostic services. These services are crucial for the early detection and management of various health conditions. These services include routine blood tests, specialized tests for infections, and preventive screenings. The availability of comprehensive diagnostic services helps in timely diagnosis. This is vital for effective treatment and better health outcomes.The importance of Dr Lal PathLabs extends beyond just providing diagnostic services. The company has been a pioneer in the Indian diagnostics industry since its inception in 1949. With over seven decades of experience, Dr Lal PathLabs has built a reputation for reliability and quality. This long-standing presence in the market has allowed the company to develop a deep understanding of the population's healthcare needs. As a result, it can offer relevant and high-quality services.
Headquartered in New Delhi, Dr Lal PathLabs operates an extensive network of laboratories and collection centers across India. This widespread presence ensures that people from various regions have access to essential diagnostic services. The company’s network includes over 200 clinical laboratories, over 2,500 patient service centers, and around 6,500 pick-up points. This extensive reach makes it easier for patients to get their tests done conveniently without traveling long distances.
The company was founded by the late Dr. S. K. Lal, a visionary who recognized the need for reliable diagnostic services in India. Today, Dr Lal PathLabs is promoted by Dr. Arvind Lal, who continues to uphold the legacy of quality and innovation established by his father. Under his leadership, the company has embraced modern technologies and practices. This commitment ensures that it remains at the forefront of the diagnostics industry.
The company’s commitment to quality is evident in its accreditation and certifications. Dr. Lal PathLabs is accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). Additionally, it holds accreditation from the College of American Pathologists (CAP). These accreditations are a testament to the company’s adherence to international standards of quality and reliability. Patients can trust that the test results from Dr Lal PathLabs are accurate and dependable.
While Dr Lal PathLabs is a significant player in the Indian diagnostics market, it is not currently the largest in terms of market share or market capitalization. However, it is recognized for its extensive network and high-quality services. The company’s focus on quality and customer satisfaction has helped it build a loyal customer base.
Promoter shareholding is an essential aspect of Dr Lal PathLabs’ corporate structure. The promoters hold a significant stake in the company, ensuring strong governance and strategic direction. This promoter involvement is crucial for maintaining the company’s vision and values. These values are centered around quality, innovation, and customer satisfaction.
The company also maintains a robust management team and a clear governance framework to ensure transparency and accountability. This solid corporate governance structure helps maintain stakeholders' trust, including patients, investors, and employees.
FAQ’s
What is the share price of Dr Lal Pathlabs Ltd today?
Dr Lal Pathlabs Ltd share price as on 18 Nov 2025 is ₹ 3133.7
What is the Market Cap of Dr Lal Pathlabs Ltd?
The market cap of Dr Lal Pathlabs Ltd stock is ₹26,458.82 Cr.
What is the PE Ratio of Dr Lal Pathlabs Ltd?
The Price to Earnings (P/E) Ratio of Dr Lal Pathlabs Ltd is 41.66
What is the PB Ratio of Dr Lal Pathlabs Ltd?
The Price to Book (P/B) Ratio of Dr Lal Pathlabs Ltd is 9.71
What is the 52 week high of Dr Lal Pathlabs Ltd Share Price?
The 52 week high of Dr Lal Pathlabs Ltd share price stands at ₹3,540
What is the 52 week low of Dr Lal Pathlabs Ltd Share Price?
The 52 week low of Dr Lal Pathlabs Ltd share price stands at ₹2,293.55
How can I buy shares of Dr Lal Pathlabs Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Dr Lal Pathlabs Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
